Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. Company
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of ophthalmia and hepatitis. Net sales break down by category of products as follows:

- chemical medicine products and biopharmaceutical drugs (97.4%);

- other (2.6%).

Number of employees : 24 108 people.
Sales per Business
20192020Delta
Modern Chinese Medicines and Chemical Medicines26 842.1097.7%25 944.0097.6% -3.35%
Others637.262.3%628.242.4% -1.42%
HKD in Million
Sales per region
20192020Delta
China27 479.40100%26 572.20100% -3.3%
HKD in Million
Managers
Name Title Age Since
Yi Li Chief Executive Officer & Executive Director 59 2020
Hsuan Tse General Manager-Information Management 50 2003
Wei Nong Ye General Manager-Research & Development 57 2002
Mao Li Chief Medical Officer - 2021
Zheng Fei Lu, Dr. Independent Non-Executive Director 57 2007
Da Kui Li Independent Non-Executive Director 76 2004
Hong Lu Independent Non-Executive Director 51 2015
Lu Fu Zhang Independent Non-Executive Director 64 2015
Kwok Tung Li, Dr. Independent Non-Executive Director 65 2020
Hsin Tse Executive Director & Vice President 50 2013
Members of the board
Name Title Age Since
Y Y Tse Chairman 28 2015
Ping Tse Senior Vice Chairman 69 2020
Hsin Tse Executive Director & Vice President 50 2013
Cheung Ling Cheng Vice Chairman 57 2017
Zheng Fei Lu, Dr. Independent Non-Executive Director 57 2007
Da Kui Li Independent Non-Executive Director 76 2004
Ming Qin Li Executive Director & Vice President 62 2015
Zhou Shan Tian Executive Director 56 1997
Shan Chun Wang Executive Director 52 2015
Hong Lu Independent Non-Executive Director 51 2015
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 18,861,499,230 9,882,638,595 52.4% 0 0.0% 52.4%
Shareholders
NameEquities%
S Y Tse 4,050,000,000 21.5%
Y Y Tse 2,279,254,761 12.1%
Ping Tse 1,584,723,124 8.40%
GIC Pte Ltd. (Investment Management) 941,876,116 4.99%
Cheung Ling Cheng 880,034,750 4.67%
The Vanguard Group, Inc. 302,048,460 1.60%
BlackRock Fund Advisors 205,844,500 1.09%
Hsin Tse 166,247,000 0.88%
E Fund Management Co., Ltd. 161,993,750 0.86%
Norges Bank Investment Management 137,634,061 0.73%
Holdings
NameEquities%Valuation
ASCENTAGE PHARMA GROUP INTERNATIONAL (6855) 4,586,400 1.81% 27,757,535 USD
KAROLINSKA DEVELOPMENT AB (PUBL) (KDEV) 75,727,285 43.5% 25,767,723 USD
Markets and indexes
- Primary Listing
- Hang Seng /
Stock Exchange Codes
- Bloomberg Code :  1177:HK
- Reuters Code :  1177.HK
- Datastream Code :  
Company contact information
Sino Biopharmaceutical Limited
Rm 4109, Office Tower, Convention Plaza, 1 Harbour Road
HK- Wanchai, Hong Kong

Phone : +852 2802 9886
Fax : +852 2880 0847
web site : http://www.sinobiopharm.com/
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-12.00%15 948
JOHNSON & JOHNSON9.42%453 418
ROCHE HOLDING AG12.49%335 069
PFIZER, INC.16.30%239 525
NOVARTIS AG-0.16%224 495
ELI LILLY AND COMPANY44.22%223 011
ABBVIE INC.8.54%209 951
NOVO NORDISK A/S34.04%209 588
MERCK & CO., INC.-5.95%194 791
ASTRAZENECA PLC12.89%179 111
BRISTOL-MYERS SQUIBB COMPANY9.87%151 437
AMGEN INC.5.45%139 306
SANOFI10.39%128 907
GLAXOSMITHKLINE PLC5.65%98 310
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-26.95%61 568
BAYER AG4.43%59 749
JIANGSU HENGRUI MEDICINE CO., LTD.-41.45%54 376
TAKEDA PHARMACEUTICAL COMPANY LIMITED-1.94%53 817
DAIICHI SANKYO COMPANY, LIMITED-38.91%38 941
ASTELLAS PHARMA INC.9.10%32 266